Marshall Wace, LLP Axsome Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $90.8 Billion
- Q3 2025
A detailed history of Marshall Wace, LLP transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 378,024 shares of AXSM stock, worth $52.8 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
378,024
Previous 56,716
566.52%
Holding current value
$52.8 Million
Previous $5.92 Million
675.52%
% of portfolio
0.05%
Previous 0.01%
Shares
12 transactions
Others Institutions Holding AXSM
# of Institutions
414Shares Held
36.8MCall Options Held
752KPut Options Held
567K-
Vanguard Group Inc Valley Forge, PA4.18MShares$584 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.3MShares$461 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA1.33MShares$186 Million0.03% of portfolio
-
Rtw Investments, LP New York, NY1.12MShares$156 Million1.82% of portfolio
-
Macquarie Group LTD Australia, C31.08MShares$151 Million0.16% of portfolio
About Axsome Therapeutics, Inc.
- Ticker AXSM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,878,000
- Market Cap $5.99B
- Description
- Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...